Physician profile
Stacy D Travis
NPI 1154322295
$27,466.94
in general payments reported to CMS, 2019-2025
32 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $247 · 2021: $145 · 2022: $7,353 · 2023: $18K · 2024: $1,259 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $1,252 · Travel and Lodging: $783 · Consulting Fee: $175 · Education: $72.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,000.00 |
| Food and Beverage | $1,251.89 |
| Travel and Lodging | $783.32 |
| Consulting Fee | $175.00 |
| Education | $72.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $25,313.88 | 2022-2024 | Gelpoint V-Path |
| Abbvie INC. | $478.23 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Therapeuticsmd, INC. | $179.95 | 2019-2022 | |
| Exeltis, USA INC. | $162.16 | 2023-2025 | Slynd |
| Coopersurgical, INC. | $147.45 | 2020-2025 | Endosee, Paragard T 380a |
| Pfizer INC. | $123.94 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $111.33 | 2022-2023 | |
| Millicent US INC | $99.14 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $89.21 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $75.68 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $70.89 | 2019-2024 | Veozah |
| Alydia Health | $60.43 | 2021 | |
| Baxter Healthcare | $48.67 | 2022-2025 | Perclot |
| Avion Pharmaceuticals | $48.61 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $47.58 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $46.57 | 2021-2022 | |
| Exact Sciences Corporation | $45.75 | 2024 | Cologuard Collection Kit |
| Organon LLC | $39.49 | 2023-2025 | Jada System, Nexplanon |
| Novo Nordisk INC | $37.44 | 2019-2020 | |
| Minerva Surgical, INC | $27.80 | 2020 | |
| Merck Sharp & Dohme LLC | $27.35 | 2019-2023 | Gardasil 9 |
| Allergan, INC. | $26.36 | 2019-2020 | |
| Duchesnay USA Incorporated | $24.18 | 2019 | |
| Daiichi Sankyo INC. | $23.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.85 | 2022 | |
| Roche Diagnostics Corporation | $19.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.63 | 2021 | |
| Medtronic, INC. | $18.10 | 2022 | |
| Eisai INC. | $12.53 | 2019 | |
| Molnlycke Health Care US, LLC | $11.61 | 2022 | |
| Mission Pharmacal Company | $11.38 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.